Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Covalent Bruton tyrosine kinase inhibitors (BTKi’s) and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL), especially those with biologically adverse disease. Patients with CLL resistant to their first targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Lew, Thomas E., Lin, Victor S., Cliff, Edward R., Blombery, Piers, Thompson, Ella R., Handunnetti, Sasanka M., Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Huang, David C. S., Seymour, John F., Roberts, Andrew W., Anderson, Mary Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945613/
https://www.ncbi.nlm.nih.gov/pubmed/34478505
http://dx.doi.org/10.1182/bloodadvances.2021005083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945613/
https://www.ncbi.nlm.nih.gov/pubmed/34478505
http://dx.doi.org/10.1182/bloodadvances.2021005083

Ejemplares similares